Eagle’s Eye View: ESC Congress 2023 Follow-Up

In this special edition of the View, Dr. Eagle summarizes the top trials that were presented at the ESC Congress in Amsterdam from Friday, Aug. 25 through Monday, Aug. 28.    Dr. Eagle discusses STEP-HFpEFF, evaluating the targeting of therapy in patients with the obesity phenotype and heart failure with preserved ejection fraction. He then looks at STOP-DAPT3 exploring the benefit of the prasugrel monotherapy without aspirin as compared with the 1-month dual therapy with aspirin and prasugrel. ESC also presented ONCO DVT, looking at the optimal duration of anticoagulation therapy, and at ILLUMEN-IV investigating the superiority of an Optical Coherence Tomography (OCT)-guided stent implantation strategy.   Dr. Eagle also looks at three trials with negative results that still offer important insights, including ARREST, comparing survival in hospital discharge between two standards of care after arrival at the hospital, ECLS-Shock investigates extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock and COP-AF, exploring colchicine for the prevention of perioperative atrial fibrillation in patients undergoing thoracic surgery.   Subscribe to Eagle’s Eye View